Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Invest Dermatol. 2021 Mar 23;141(9):2208–2218.e14. doi: 10.1016/j.jid.2021.02.749

Figure 3. Activated T-cells exhibit an IL-22 phenotype in PN.

Figure 3.

PBMCs from PN (n=4) and healthy subjects (n=5) were stimulated with PMA and ionomycin combined with protein transport inhibitor for 4hrs. The cells were analyzed for intracellular cytokine expression by flow cytometry. a, Representative flow cytometry histograms of intracellular IL-22 cellular expression versus unstained control (Ctrl). b, Mean fluorescence intensity (MFI) of IL-22 expressing CD3+ cells (median ± ICR). c, Percentage of IL-22 expressing T-cell subsets including CD4, CD8, γδ T-cells, and iNKT – cells ± SEM. d, Representative flow cytometry histograms of intracellular TNF cellular expression versus unstained control (Ctrl). e, Mean fluorescence intensity (MFI) of TNF expressing CD3+ cells (median ± ICR). f, Percentage of TNF expressing T-cell subsets including CD4, CD8, γδ T-cells, and iNKT-cells ± SEM. g, Representative flow cytometry histograms of intracellular IL-4 cellular expression versus unstained control (Ctrl). h, Mean fluorescence intensity (MFI) of IL-4 expressing CD3+ cells (median ± ICR). i, Percentage of IL-4 expressing T-cell subsets including CD4, CD8, γδ T-cells, and iNKT-cells ± SEM. *P<0.05, healthy controls versus PN subjects, as calculated by a non-parametric Mann Whitney U- test. ns = non-significant.